Events

More than just subjective intention is relevant to the defence of honest concurrent use in trade mark law, non-bank lender Firstmac has told the High Court in its dispute with buy now, pay later giant Zip Co.

Former Carlton Football Club president and ex-chief executive of PricewaterhouseCoopers, Luke Sayers, has been sued by his estranged wife for defamation over a lewd social media post that eventually led to his resignation from the football club.

An appeals court has handed BHP a win in a dispute with Aquila Steel over the boundary between their neighbouring mining tenements, rejecting Aquila’s “fanciful” argument about the construction of a 58-year-old document.

A Sydney developer has filed proceedings against the environment minister after a delegate found its proposal to build two towers in Parramatta would have “clearly unacceptable” impacts on views from Australia's oldest public building. 

A Hong Kong company has won its bid to claw back funds from the family of a deceased debtor who transferred a Sydney property to his wife as part of a purported separation agreement, with a court finding the transaction was intended to defraud creditors.

BHP has filed a High Court challenge to orders requiring it to pay labour hire workers at mines in central Queensland the same as its workers.

The mayor of a Perth local council has been awarded $250,000 in damages for defamation against a constituent who made a series of Facebook posts falsely alleging that he was misusing a public office.

More than 38,000 retail investors have received nearly $40 million in refunds after an ASIC investigation found “widespread weaknesses” in how issuers of contracts for difference products comply with their obligations. 

A court has largely set aside examination orders against executives and solicitors for oil and gas company Moreton Resources and MRV Metals, finding they were an abuse of process. 

Merck KGaA has failed to block Pfizer’s 'Abrysvo' trade mark for its RSV vaccine, with a delegate finding no likelihood of confusion with the mark for Merck’s Mavenclad MS drug despite their visual similarities.